The Role of Complementary and Alternative Medicines in the Treatment and Management of COVID-19 by Saxena, Bhagawati
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







The Role of Complementary 
and Alternative Medicines in the 




Interception of coronavirus disease 2019 (COVID-19) into our life and its rapid 
global expansion, humanity has succumbed to a vulnerable position. COVID-19 
is proclaiming millions of lives, underscores the urgent need for more effective 
therapeutic interventions. This disease created catastrophe and developments of 
new drugs and vaccines take a long duration. Hence, scientists and medical soci-
ety turned their heads towards different approaches of treatment, referred to as 
complementary and alternative medicine (CAM) for eradicating the deadly virus. 
Ayurveda, herbal medicines, nutritional supplements, naturopathy, and yoga are 
some of the CAMs which have emerged as a ray of hope in these times. The under-
standing of the COVID-19 pathogenesis and its impact on immunity will progress 
the effective management of this lethal infectious disease. The host immune 
response has an elementary function of defense against the majority of infectious 
diseases including COVID-19. This chapter focuses on the utilization of various 
CAMs (Ayurveda, yoga, herbs, phytochemicals and nutritional supplements) in 
COVID-19 treatment. An additional attempt has been made in this chapter on the 
potential of CAMs to assist in improving immunological reactions against infections 
and thus may be an efficient approach in the prevention and/or management of 
severe acute respiratory syndrome coronavirus 2 infections.
Keywords: COVID-19, SARS-CoV-2, Complementary and Alternative Medicines, 
Innate immunity, Adaptive immunity, Micronutirents
1. Introduction
The coronavirus disease 2019 (COVID-19) proclaiming millions of lives, is an 
infectious respiratory disease affecting the lungs. COVID-19 is devastating mainly 
in patients of old age and with co-morbidities like obesity, cardiovascular complica-
tions etc. COVID-19 is caused by recently recognized coronavirus termed as severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 outbreak 
was instigated in December 2019 from the Wuhan city of China, which is rapidly 
spreading worldwide and badly impacted the entire world [2]. The COVID-19 pan-
demic is currently the prevalent world health crisis and a daily large number of new 
cases is reported around the world [3, 4]. By June 24, 2021, the mortality rates raised 
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to 3.9 million among 180 million confirmed cases of COVID-19. Currently, the 
world healthcare system is in severe crisis due to the constant and varied challenges 
created by COVID-19. Initially, due to the lack of understanding regarding novel 
coronavirus and vaccines or any treatment for the COVID-19, governments officials 
globally implemented various non-pharmaceutical interventions (NPIs), such as the 
utilization of masks, social distancing, hand-washing, remote working, closures of 
schools and colleges, restrictions on public gatherings, fourteen days quarantines, 
for the slow transmission of the disease [5]. These measures are found to be effec-
tive in mitigating the number of cases [6, 7], however, they lead to a considerable 
impact on the social, economic [8] and psychological wellbeing of the society [9].
Government’s professionals, pharmaceutical companies and professionals in the 
health care system are taking great efforts to manage and combat the disease across 
the world. To alleviate the burden on society, a massive effort is being made by health 
care professionals worldwide to develop and get access to different vaccines [10, 11]. 
Vaccination has been started around the globe after a year of the first reported cases of 
COVID-19 [12]. Vaccines were developed and have been found successful in decreasing 
the number of patients affected with COVID-19 as well as the severity of the disease, 
however, it is not completely avoiding the risk of being affected with COVID-19. 
Additionally, new strains of coronavirus are also gradually identified. Recently it is 
found that novel coronavirus is having various mutations. This means that there are 
slight changes in the genetic composition of the virus. The Delta-plus variant is a 
mutated version of the Delta variant (the virus that wreaked havoc in the second wave). 
Delta plus is considered highly infectious. The virus can potentially dodge immune 
response, vaccines and antibody therapies. However, more research has to be done in 
this context. Few cases have been recorded in some states of India. The Government 
official has classified it as a Variant of Concern (VOC). There is no certainty regarding 
delta plus and the current numbers cannot determine any particular trend. Certain 
vaccines work against the Delta Plus variant, but they show 3 to 8 times less efficacy 
as compared to other variants. There are no conclusive reports about these variants 
but we should not keep our guards down [13, 14]. The United States Food and Drug 
Administration (U.S. FDA) approved the antiviral drug, remdesivir (Veklury), for 
treating COVID-19 affected patients requiring hospitalization. Remdesivir approved to 
be administered in the health care setting or hospital that is efficient enough of afford-
ing acute care comparable to inpatient hospital care. This approval of using remdesivir 
for treating COVID-19 does not include the entire population rather it is only approved 
for hospitalized patients who are adults and pediatric (≥12 years of age) with a body-
weight of at least 40 kilograms [15]. Moreover, health care systems are facing huge 
difficulties in combating the enormous demands of medicines and vaccines. Thus, 
providing additional therapies for preventing and curing the disease is an important 
step in combating this pandemic. Currently, the worldwide impetus is unabated, and a 
third wave is also predicted.
India and China are known for their rich history of traditional medicine [16]. 
Indian households are being considered as a hub of natural products, consisting of a 
plethora of pharmacologically active ingredients inspired by the traditional medica-
tion system (Ayurveda) [16]. Complementary and alternative medicines (CAMs) 
have emerged as a ray of hope in these times [17]. The following book chapter focuses 
on ‘the role of CAMs in the prevention, treatment and management of COVID-19’.
2. Pathogenesis of COVID-19
The recently identified SARS-CoV-2 is a new member added into the family of 
β-coronavirus with earlier known members like Severe Acute Respiratory Syndrome 
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Coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome Coronavirus 
(MERS-CoV), which results in severe pulmonary pneumonia and potentially deadly 
acute respiratory distress syndrome (ARDS). The large population of COVID-19 
patients is asymptomatic. Six prominent symptoms include dry cough, malaise, 
fatigue, fever, dyspnea, secretion or sputum among various clinical manifestations 
noticed in patients infected with SARS-CoV-2. The gastrointestinal symptoms 
consist of vomiting, anorexia, and diarrhea in the patients affected with COVID-19. 
Pathogenesis of COVID-19 is classified into three discrete clinical phases based 
on the cells/tissue being infected. These three phases include asymptomatic state, 
upper and conducting airway response and hypoxia, ground-glass infiltrates and 
progression to ARDS. In Phase, I of asymptomatic state inhaled SARS-CoV-2, bind 
to the receptor present on the epithelial cells i.e., angiotensin-converting enzyme-2 
(ACE-2) on the nasal cavity and begin reproducing [18]. There is local propagation 
of the COVID-19 virus and an inadequate innate immunity in the asymptomatic 
stage. In phase II, there is an occurrence of the upper airway and conducting 
airway infection. In this phase or stage, there is a robust immune response when 
the virus migrates and propagates down the conducting duct and along the respira-
tory tract. Epithelium of the upper and conducting airway infected virally results 
in the release of cytokines [19]. During this phase, clinical manifestations are 
observed. Predictions and monitoring of the subsequent course of the disease may 
be improved by determining the host immune responses. In most of the patients 
infected with SARS-CoV-2, the infection will be mild and mostly limited to the 
upper and conducting airways [20]. These patients do not require hospitalization 
and may be monitoring of patients at home with conventional symptomatic treat-
ment will be adequate [19]. In the third stage or phase III, there will be ground-glass 
infiltrates, hypoxia and progression to ARDS. Typically, around 20% of the patients 
infected with SARS-CoV-2 advance to the severe stage and develop pulmonary 
infiltrates and ARDS. In this stage, the virus reaches and infects the gas exchange 
unit of the lungs i.e., alveolar type II cells mainly in the subpleural region of lungs 
[21]. Once the virus reaches the type II alveolar cells self-replicating pulmonary 
toxins are released and it results in apoptosis and cell death [22]. This in turn causes 
diffuse alveolar injury, with a few multinucleated large cells and a fibrin membrane 
rich in hyaline [23, 24]. Extensive scarring, fibrosis, and various kinds of ARDS may 
occur from aberrant wound healing. Improvement requires epithelial cells regenera-
tion and robust innate and adaptive immune responses. Patients with older age or 
co-morbidities are at greater risk due to weakened capacity to repair the damaged 
epithelium and deteriorated immune response against the virus. In the elderly, the 
mucociliary clearance is also reduced and this allows propagation and rapid spread 
into the gas exchange unit of the lungs [25].
3. Interaction of virus with the immune system
Manifestations of COVID-19 is extremely heterogeneous, with a wide clinical 
spectrum varying from asymptomatic infection through mild upper respiratory 
and conducting airways infection, to severe pneumonia leading to fatality [24, 26].  
Recognizing the machinery for the virus invasion into the host body and its inter-
action with the host immunity will facilitate the prevention and treatment of the 
COVID-19. Infection with SARS-CoV-2 has two distinct clinical phases: primary 
and secondary inflammatory phases. The primary phase involves the invasion of 
viral in the host and its replication and the inflammatory phase involves exag-
gerated host immune response towards the virus. Augmented host immune 
response eventually results in fast and uncontrolled deterioration and worsening 
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of respiration and ultimately emerges the need for hospitalization [27, 28]. SARS-
CoV-2 is a lower respiratory tract virus and enters the host through a specific 
receptor i.e., ACE-2, resulting in pneumonia in severe cases. It chiefly consists of 
four structural proteins including nucleocapsid polymer, small envelope glycopro-
tein, membrane glycoprotein and spike polymer, as well as numerous accessory 
proteins. Spike protein projected from the surface of the virus is responsible for the 
attachment with ACE-2 assists the invasion of viruses into the host cells [29]. ACE2 
is mainly expressed on the lung, kidney, intestine and epithelial cells of blood 
vessels. It is worth mentioning that spike protein is considered as the potential 
target in the vaccination against COVID-19. The innate and the adaptive immunity 
pathways are two pieces of machinery of the host immune system against foreign 
pathogens [30]. To effectively deal with and rapidly control the spread of viral 
infection, the innate immunity activates and concomitantly stimulates the adaptive 
immunological reactions. The innate system is the first-line defense against the 
pathogen which comprises of external defense mechanism (e.g. epithelial cells or 
the mucous membranes in the nasopharynx, lung, gut, periodontium and skin), 
nonspecific phagocytic leukocytes (macrophages and neutrophils) as well as serum 
proteins [30, 31]. Adaptive immune build up in a long time includes a specific 
response i.e., production of protein molecules known as antibodies that react with 
the antigens of infectious agents to eradicate the virus and to forbid progression of 
the disease to severe stages [32]. The host immune system via frequently interact-
ing innate and adaptive mechanisms defends against external pathogens. Better 
management and prevention of disease requires timely identification of disease 
as well as its influence on the immune system. The disease complexity is further 
noticeable when it is reported variability in susceptibility to severe infection and 
mortality in certain sections of the population. However, earlier literature reported 
that the viral infection alerts immune system operations and influences immuno-
globulin levels, antibody generation, phagocytosis, lymphocyte transformation 
etc. [33]. Similarly, SARS-CoV-2 also impacted the innate and adaptive immunity 
of the host.
3.1 Impact of SARS-CoV-2 on innate immunity
It has been reported in numerous studies that interleukin-6 (IL-6) is upregulated 
in patients affected with SARS-CoV-2 [24]. IL-6 is chiefly produced by monocytes 
or macrophages. IL-6 employs immune mediators and results in the cytokine storm, 
which cause tissue damage and uncontrolled systemic inflammation [34]. Moreover, 
inflammatory cytokines including chemokines, interferon-gamma (IFN-γ), IFN-γ 
induced protein 10 (IP-10), tumor necrosis factor (TNF-α), interleukin-10 (IL-10) 
and monocyte chemoattractant protein-1 (MCP-1) are observed to be augmented 
in patients affected with COVID-19 [24]. Lactate dehydrogenase is a marker of 
pyroptosis and is also found to be augmented in patients affected with COVID-19, 
and is considered to be correlated with the severity of the disease as well as the rate 
of mortality. Innate immune response was observed to be activated in COVID-19 
patients, but unsuccessful to commence robust interferon (IFN) responses. The 
deficient of IFN responses could probably result in insufficiency in confining the 
viral load and viral infection at the initial stage of disease progression [34]. There is 
limited literature regarding the mechanisms underlying the SARS-CoV-2 induced 
mitigation of IFN responses. Macrophages play important role in immune responses 
against viral infection. ACE2 receptors are found to be expressed on the surface of 
macrophages [35]. This leads to increased susceptibility of macrophages to SARS-
CoV-2 infection. This signifies that macrophages may serve as a possible reservoir of 
the COVID-19 virus [36].
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3.2 Impact of SARS-CoV-2 on adaptive immunity
Stimulation of the innate immunity subsequently activates the adaptive immu-
nity. Thymus cells (T cells) and bone marrow- or bursa-derived cells (B cells) are 
key players in adaptive immunity. Effector T cells mediate cellular response against 
the virus by either directly killing the cells infected with the virus or by discharg-
ing regulatory and pro-inflammatory mediators. B cells mediate the humoral 
responses by producing neutralizing antibodies (NAbs). The released NAbs in 
turn obstruct the interaction between the spike protein of SARS-CoV-2 and ACE2 
expressed on the surface of the cell membrane and thus block the invasion of the 
virus into the host cell. On the contrary, the virus-specific antibodies interact with 
complementary receptors expressed on the exterior of the host cell and thus assist 
the entrance of the virus into the host cells. This is termed antibody-dependent 
enhancement (ADE) [37]. The NAbs titer is reported to be associated with disease 
severity [38]. However, there is a range of levels of NAbs among various patients, 
demonstrating the individual variation in immune responses towards viral infec-
tion. Cellular immunity is another intend of the adaptive immune system is against 
viral infections including the cluster of differentiation 4 (CD4) and the cluster of 
differentiation 8 (CD8) positive T cells. CD4 and CD8 are glycoproteins that serve 
as a co-receptor for the T-cell receptor (TCR). CD4+ T releases cytokines, which 
help cytotoxic T cells and B cells. On the other hand, the CD8+ T cells after being 
activated eradicate the infected cells. Depletion as well as the exhaustion of periph-
eral CD4+ and CD8+ T cells are reported in COVID-19 patients [39]. This depletion 
and exhaustion of T cells may be due to the augmented level of IL-6 in COVID-19 
patients [40].
4.  Management of COVID-19 with the use of complementary and 
alternative medicines (CAMs) endorsement
Complementary and Alternative Medicine (CAM) is an umbrella term for a 
broad range of substances and treatments which consist of a cluster of a variety 
of medic and health care supplies, orders, and actions not characterized under 
the conceptual framework of medicines. The definition of CAM throughout the 
literature is not consistent. However, the National Centre for Complementary 
and Alternative Medicines (NCCAM) of the National Institute of Health (NIH) 
defines CAM as “a group of diverse medical and health care systems, products, 
and practices that are not currently fall under the category of conventional 
medicine”(NCCAM, 2002) [41]. CAM is utilized either as an alternative or adjuvant 
therapy of conventional treatments.
The inclination towards using CAM in and around the world, both in terms of 
prophylactic as well as therapeutic strategies against problems related to health, 
has been augmented recently [42]. CAM is an extremely broad area that consists of 
all health beliefs, values, practices, as well as methods exterior to the streamlined 
present health care system [43]. These are further classified into five important 
categories by National Center for Complementary and Integrative Health (NCCIH). 
The first category includes alternative medical systems/whole medical systems 
(homeopathy, traditional Chinese medicine, ayurvedic medicine), the second 
category includes biologically-based therapies (probiotics, minerals, vitamins, 
phytochemicals, whole diets and functional foods, animal-derived extracts, amino 
acids, proteins and fatty acids), the third category includes manipulative and body-
based methods (chiropractic, osteopathic manipulation, reflexology and massage), 
the fourth category includes mind–body therapies; healing techniques based on 
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mind–body therapies (art, praying, meditation, dance, music) and finally the fifth 
category includes energy-oriented treatments or energy therapies or (therapeutic 
touch, Qi gong, healing touch) [44].
Greater than 80% of the population around the globe utilizes CAMs. The 
foundation of the National CAM-Center leads to a significantly augmented num-
ber of CAM-related basic research and clinical trials based on CAM therapies. 
Approximately 30% of the adult population of the U.S. [45] and 10–40% of Europe 
[46] use CAM. It is predicted that the market per annum for herbal remedies, 
consisting of raw materials and herbal products will expand by 15% and 5% 
respectively. The global market for the herbal drug is projected to be $62 billion, 
which is likely to rise to $5 trillion by 2050 [47]. Herbal remedies for boosting the 
immune system are consumed in several countries across the globe to uplift health, 
endorse the body’s defense against various infectious as well as prohibit and cure 
several infectious diseases [48]. In this section, several examples of CAMs projected 
for preventing and curing diseases are elaborated.
4.1 Methodology
Databases such as PubMed, Scopus, Embase, Google Scholar, Web of Science, 
and Cochrane were searched without time limitation to find relevant articles 
exploring the impact of CAM in COVID-19. The terms and words searched 
included “COVID-19”, “SARS-CoV-2”, “CAM”, “micronutrients”, “phytochemi-
cal”, “Ayurveda”, “extract”, “essential oil”, “herbal medicines”, “In vitro”, “In vivo”, 
“clinical trial” etc.
4.2 Ayurveda and yoga as the prophylactic and adjuvant therapy of COVID-19
To develop a preventive and curative intervention for COVID-19, the Ministry 
of Ayurveda, Yoga, and Naturopathy, Unani, Siddha, and Homeopathy (AYUSH), 
Government of India (GoI), formulated an interdisciplinary AYUSH research and 
development task force and guidelines for initiating, monitoring, coordinating 
efforts and conducting clinical studies of diverse traditional medicines against 
COVID-19 [49].
Visualizing the severity and infectivity of COVID-19, the Ministry of AYUSH, 
GoI recommended certain immunity boosters like lukewarm water, Kadha, (an 
ayurvedic preparations containing curcumin, ginger, cumin seeds, fennel seeds, 
cloves and honey) and homeopathic medicine ‘Arsenic Album 30C’ [50]. Ayurveda 
defined NPIs in addition to pharmacological as preventive measures in combating 
COVID-19. NPIs recommended by the Ministry of AYUSH include sadvritta (Sad 
means ‘good’ and vritta means ‘regimen’), healthy lifestyles, enough sleep, adequate 
physical activity, avoidance and isolation from infected persons [51]. Certain 
medicines suggested by Ayurveda include turmeric (Curcuma longa), garlic (Allium 
sativum), Ajwain or Carom (Trachyspermum Ammi) as a disinfectant for the preven-
tion of COVID-19 [52].
The nose, mouth and eyes, are the main entry portals for the droplets consisting 
of the virus, SARS-CoV-2. Before reaching and final attack on the lungs, the virus 
stays in the nose and throat region for hours. The virus is coated with fatty acid 
which helps in adhering the virus to the moist mucosal layers and thus facilitates 
its entrance into the host cells by attaching to definite receptors [53]. Ayurveda 
mentioned various interventions that interfere in these entry portals [54] for virus 
invasion to the lungs by improving the innate immunologic response of the mucus 
membranes. These measures work as “physiological masks” or “local prophylaxis” 
for obstructing the viral invasion. The common recommendation for respiratory 
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diseases written in Ayurvedic texts [55] includes consumption of hot food, hot 
water, steam inhalation, gargling, local applications and herbal decoctions with 
medicated water. These may be useful for relief in mild cases [53]. Ayurveda recom-
mended drinking hot and warm water for improving the digestion of Ama. Ama is 
a pro-inflammatory mediator of weaken metabolic disorders and is associated with 
augmented susceptibility to infections [56].
Warm oils and liquids are employed as mouth rinses (Kavala) or gargles (gan-
dusha) to thoroughly clean the mouth and throat [57]. The oily decoctions coat the 
mucosa as biofilm as well as rinse the oral cavity, tonsillar area, and pharynx. These 
decoctions also have supplementary benefits of antioxidant, immunomodulatory, 
and antimicrobial [58]. It is well known that host mucosal immunity plays a vital 
role in controlling infectious agents [59]. Literature regarding Yoga advocates Jala 
neti which implies rinsing of the nasal passage with saline water [60]. Randomized 
controlled trials (RCTs) reported the effectiveness of saline water in upper respira-
tory infections [61].
4.3 Herb/phytochemicals
Herbal products are consumed in various countries across the globe. Literature 
suggests immune-boosting properties of these herbal materials which endorse 
the normal resistance ability of the body against infectious pathogens and to 
raise health, and as well as to cure and to prohibit diverse infectious diseases 
[48]. Curcumin, a polyphenolic compound isolated from turmeric, which is a 
commonly used food colorant and spice [62], can augment the antibody reaction 
even if it is consumed at reduced doses [63]. Additionally, literature shows that 
curcumin has a promising affinity for protein binding towards SARS-CoV-2 and 
thus directly inhibit the invasion of SARS-CoV-2 into target cells [64]. The ability 
of curcumin in improving various disease conditions is attributed partially to its 
capability to modulate the immune responses [63]. Numerous reports show that 
curcumin can alter the proliferation as well as the activation of T cells [65, 66]. 
Additionally, curcumin has the potential of regulating the response and growth of 
various immune cells like natural killer (NK) cells, B cells, T cells, dendritic cells 
(DCs), macrophages and neutrophils [63]. Glycyrrhizin, an active phytochemical 
moiety found in liquorice was observed to be efficient in comparison to commonly 
used anti-virals in mitigating the replication of SARS-CoV as well as inhibiting its 
adsorption and penetration [67]. A recent in-vitro study also showed that glycyr-
rhizin is a potential inhibitor of SARS-CoV-2 replication by hindering the viral main 
protease (Mpro) [68]. Molecular docking study showed two phytoconstituents 
Somniferine and Withanoside V from Ashwagandha (Withania somnifera) [69, 70], 
Tinocordiside [70] and berberine [71] from Giloy (Tinospora cordifolia) and three 
active ingredients i.e., Vicenin, Ursolic acid and Isorientin 4’-O-glucoside 2″-O-p-
hydroxybenzoagte isolated from Tulsi (Ocimum sanctum) [70] may have an antiviral 
effect against novel coronavirus via potentially inhibiting Mpro of SARS-CoV-2.
4.4 Nutritional supplements
Recently conducted studies show that suboptimal intake of micronutrients 
and inadequate nutritional status can lead to poor immunity and consequently 
affect the severity of infections. Nutritional supplements emerge to reinforce the 
immune system. Micronutrients consisting of a variety of vitamins (A, D, C, E, B6, 
B12, folate) and minerals (iron, zinc, selenium and copper) are engaged in various 
stages of the immune responses against foreign pathogens. A study conducted in 
the United Arab Emirates (UAE) confirmed the association of low levels of vitamin 
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D3 (25(OH)D3) (<12 ng/mL) with severity and death due to COVID-19 [72]. 
Another study shows that hospitalized COVID-19 patients receiving vitamin D3 
(calcifediol) in contrast with those not consuming vitamin D3, was significantly 
linked with a lesser rate of mortality during the initial thirty days of hospitaliza-
tion [73]. Supplementation with vitamin D at high-dose may be well-tolerated, 
effective, and readily accessible for the management of COVID-19 [74]. One 
report showed that intake of a high dose of vitamin D has significantly reduced the 
inflammatory markers (neutrophil/lymphocyte ratio, ferritin, C-reactive protein 
(CRP), lactate dehydrogenase (LDH), IL-6 associated with COVID-19 without 
any side effects [75]. A study confirmed that deficiency of vitamin D is correlated 
with severe lung injury, disease prolongation and risk of mortality, in COVID-19 
patients [76]. Another study shows that combination therapy of vitamin D with 
vitamin B12 and magnesium in geriatric patients with COVID-19 was correlated 
with a considerable decline in the proportion of patients with clinical deteriora-
tion and requiring intensive care support and oxygen support [77]. Vitamin D was 
found to modulate innate and adaptive immune systems [78, 79]. It augments the 
innate immune responses while attenuates the adaptive immune responses [78]. 
Vitamin D metabolites directly target the adaptive immune cells [80] and it is an 
important part of intricate features that control the immune response against infec-
tion [81]. These findings necessitate examining the level of vitamin D in pediatric 
as well as geriatric persons to maintain it at optimum levels for the prevention of 
SARS-CoV-2 infection.
In addition to the consumption of higher doses of vitamin D3, previously it was 
also stated that coronavirus pandemic can be considerably controlled by the utiliza-
tion of high amounts of vitamin C. Significantly low levels of vitamin C in patients 
affected with COVID-19 were found and daily supplementation of 100 mg/kg is 
highly recommended [82]. A high dose of intravenous vitamin C might repress 
cytokine storms associated with COVID-19, and facilitate improving pulmonary 
function and lessen the risk of ARDS associated with COVID-19 [83]. As SARS-
CoV-2 was found to affect the host immune system, it seems crucial to boost the 
natural immunity and antioxidant capacity to lessen the effect of any virus infec-
tion. Vitamin C is known for its ability to activate the immune system. Therefore it 
seems promising to administered vitamin C concomitantly with other medications 
to cure the infection in acute conditions. The ingestion of vitamin C orally up to the 
daily threshold of bowel tolerance seems to be effective for the majority of persons. 
However, intravenous administration of vitamin C is suggested for serious cases. 
On the other side, there are certain reports, claiming that the overstimulation of 
immune cells in COVID-19 leads to cytokine storm which ultimately causes lung 
injury following pneumonia. Certain clinical investigations also suggested that 
intravenous administration of vitamin C in high-dose can be a safe and effective 
choice for the management of COVID-19 infection in its early stages. Even though 
previous literature recognized and approved the antiviral activity of vitamin C, 
but its impact has not been studied widely and, limited information is available on 
its effect on coronavirus. Moreover, some studies show that adjunctive intravenous 
administration of vitamin C for the treatment of infection in critically ill COVID-19 
patients was unable to reduce the rate of mortality, ventilator settings, the require-
ment of vasopressor, etc. [84]. Therefore although vitamin C is vital for lessening 
the inflammatory response and assists in boosting the immune system of the host, 
there is a lack of substance to support that utilization of vitamin C at a high dose 
can be successful in the prevention or management of COVID-19. Moreover, as 
Therapeutic Goods Administration (TGA) [85] declared that more studies are 
required for any recommendation for utilizing intravenous vitamin C in the man-
agement of COVID-19. In addition to vitamin C and vitamin D3, it was reported 
9
The Role of Complementary and Alternative Medicines in the Treatment and Management... 
DOI: http://dx.doi.org/10.5772/intechopen.100422
that vitamin K antagonist regular use was correlated with augmented mortality in 
hospitalized elderly patients affected with COVID-19 [86].
Studies show that treatment with zinc as adjuvant therapy was appeared to be 
feasible and safe for the management of COVID-19. However, the infusion of zinc 
causes limited infusion site irritation on the periphery [87]. Zinc supplement was 
found to be efficiently clear the SARS-CoV-2 from the nasopharynx in a lesser time 
than other symptomatic therapy [88]. Zinc cation (Zn2+) coupled with zinc iono-
phores pyrithione and found to inhibit RNA polymerase of coronavirus and thus 
block the replication of the virus [89]. Additionally, zinc also mitigates the invasion 
of the virus by escalating the cell membrane stability as well as stimulate interferon-
alpha (IFN-α) and IFN-γ formation and attenuate tumor necrosis factor (TNF) 
and mononuclear cells [90]. Apart from zinc, iron also plays a vital component of 
enzymes involved in the stimulation of immune cells, lower levels of iron was found 
to influence severe symptoms associated with COVID-19. Selenium contributes 
to adaptive immunity by boosting the production and development of antibodies. 
Lack of selenium can lessen antibody production, compromised cellular immunity, 
attenuated the cytotoxicity of NK cells, and decreased response to vaccination. 
Oxidative stresses alter the viral genome from a mildly pathogenic form to a highly 
virulent form of the virus in the host. Selenium is a known anti-oxidant. Hence 
selenium with vitamin E and a cluster of certain enzymes scavenges the free radicals 
and lessens the oxidative stress and thus as a result, the adjuvant therapy of sele-
nium may be considered for the treatment of COVID-19 infection [91].
5. Limitations
Literature shows that people who either have positive attitudes towards CAM 
or those who consume CAM are unwilling to comply with conventional therapy, 
most prominently the vaccinations and to follow the official COVID-19 guidelines 
[92–98]. It has been reported that the optimistic attitudes towards CAM are corre-
lated with negative attitudes towards vaccination is not evidence-based but because 
of an underlying outlook on health or perhaps a reluctance to stick to conventional 
therapy [93–95]. Those who utilize CAM perceived CAM as a natural, safe approach 
to improve the host immunity, while vaccines are considered as a risky option [94]. 
Additionally, both anti-vaccination attitudes and higher utilization of CAM are 
correlated to the poor trust of individuals towards the healthcare system or medical 
authorities [92].
6. Summary/conclusion
It is apparent from the above findings, that the understanding of the COVID-19 
pathogenesis and its impact on immunity will progress the management of this 
lethal infectious disease. As per the earlier studies, the host immune response has an 
elementary function of defense against the majority of infectious diseases including 
COVID-19. In this chapter specifically attempt has been made on the utilization of 
various NPIs, herbs, phytochemicals and micronutrients which has the potential 
to assist in the prevention and/or management of SARS-CoV-2 infection. Thus 
utilization of CAMs may be an efficient approach in improving immunological 
reactions against infections. Moreover, the consumption of vitamins and minerals 
was observed to be favorable in improving the immune system and its function. 
Although, certain clinical studies reported the success of CAMs in the treatment, 
prevention and management of COVID-19, additional studies through clinical 
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analysis as well as consumers’ experience on CAMs are essential to draw strong 
conclusions in the success of utilization of CAMs for treatment, prevention and 
management of COVID-19.
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